Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by analysts at Oppenheimer Holdings, Inc. in a note issued to investors on Thursday, September 7th. They presently have a $203.00 target price on the medical research company’s stock. Oppenheimer Holdings, Inc.’s price objective points to a potential upside of 8.28% from the stock’s previous close.
A number of other brokerages have also commented on AMGN. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Deutsche Bank AG reaffirmed a “hold” rating and issued a $174.00 target price (up previously from $172.00) on shares of Amgen in a research report on Wednesday, July 26th. Cann reaffirmed a “buy” rating and issued a $203.00 target price (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Cowen and Company reissued an “outperform” rating and issued a $209.00 price objective on shares of Amgen in a research report on Saturday, July 22nd. Finally, Credit Suisse Group set a $177.00 price objective on shares of Amgen and gave the company a “hold” rating in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Amgen presently has an average rating of “Buy” and a consensus price target of $186.14.
Amgen (NASDAQ AMGN) opened at 187.47 on Thursday. Amgen has a 1-year low of $133.64 and a 1-year high of $191.10. The company’s 50-day moving average price is $175.31 and its 200 day moving average price is $169.32. The firm has a market capitalization of $136.79 billion, a PE ratio of 17.08 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period last year, the business posted $2.84 earnings per share. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities analysts anticipate that Amgen will post $12.57 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. TrimTabs Asset Management LLC lifted its position in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after acquiring an additional 288 shares during the period. Alpha Omega Wealth Management LLC lifted its position in shares of Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after acquiring an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. lifted its position in shares of Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after acquiring an additional 4 shares during the period. Phocas Financial Corp. acquired a new position in shares of Amgen during the 2nd quarter valued at $110,000. Finally, American Beacon Advisors Inc. acquired a new position in shares of Amgen during the 1st quarter valued at $106,000. Institutional investors own 78.09% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.